After THE DARK REPORT’S Executive War College on Medical Laboratory Networking in New Orleans on May 20-21, two other interesting laboratory meetings are scheduled. First up is the 15th annual symposium presented by the University of Michigan’s Department of Pathology. Scheduled for May 28-30 in Ann Arbor, Michigan, it is titled “Automated Information Management In the Clinical Laboratory.” It is the biggest meeting of the year which focuses entirely on laboratory information systems and related topics. On June 18-20, ARUP Laboratories and the University of Utah School of Medicine will present a program entitled “Update in Laboratory Medicine And Management.” Presentations are structured to address two themes: science in the laboratory and business management in the laboratory.
Provocative changes are taking place in the world of automated cytology. Even as pathologists and cytologists debate the merits of automated cytology systems, such products continue to make in roads. The latest news is that NeoPath, Inc. of Redmond, Washington gained approval on March 19, 1997 from the Ministry of Health and Welfare to sell its AutoPap System® as a primary screener in Japan.
This is a major development. Japan is the first nation to approve an automated cytology system for primary screening of Pap smears. Nikon Corp. is NeoPath’s distributor in Japan. Nikon handles regulatory issues and provides local support. It appears that NeoPath’s choice of Nikon was a wise strategic decision. Besides the credibility that comes with Japan’s decision, the 12 million Pap smears screened annually in that nation represents a lucrative market for NeoPath.
When SmithKline Beecham Clinical Laboratories (SBCL) sold its dialysis testing business last f all to Bio-Reference Laboratories of Elmwood Park, New Jersey, it didn’t take Bio-Reference Labs long to decide that the purchase was not “as represented.” Bio-Reference sued SBCL in December, claiming “breach of contract, misrepresentation and fraud” relating to the sale of assets. The lawsuit alleges that SBCL fraudulently concealed the nature and extent of the federal investigation which resulted in SBCL’s $325 million federal settlement in February. This negatively affected the dialysis accounts and revenues SBCL sold to Bio-Reference.
BACK IN THE LAB BUSINESS
After several year’s absence, former Damon executive Tom Liccardi has returned to the laboratory industry. He recently assumed duties as Director of Sales and Marketing at Physicians Clinical Laboratories in Sacramento, California.